Abigail R Kennedy

This inventor holds 16 USPTO granted patents and 5 published patent applications, plus 4 CIPO patents and 7 EPO patents. Top assignees: Exelixis, Inc., Symphony Evolution, Inc., Other. Active years: 2009-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Abigail R Kennedy. Retrieved from https://idiyas.com/inventor/abigail-r-kennedy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 5)

% Patents Active = 62.5

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 1)

Average Co-Inventor Count = 11.7

ph-index = 6

Forward Citations = 155(Granted Patents)

Location History:

San Leandro, CA (US) (2009 - 2019)
Oakland, CA (US) (2010 - 2023)

Company Filing History:

Symphony Evolution, Inc.

patents

1 out of 834,513

Other

patents

Years Active: 2009-2023

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11597699 - MEK inhibitors and methods of their use (2023-03-07),

2. 10266518 - Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof (2019-04-23),

3. 9796704 - Substituted quinazolines as receptor-type kinase inhibitors (2017-10-24),

4. 9359332 - Processes for the preparation of substituted quinazolines (2016-06-07),

5. 8697737 - Raf modulators and methods of use (2014-04-15),

6. 8658654 - Receptor-type kinase modulators and methods of use (2014-02-25),

7. 8372851 - Pyrazolo pyrimidines as casein kinase II (CK2) modulators (2013-02-12),

8. 8362002 - Azetidines as MEK inhibitors for the treatment of proliferative diseases (2013-01-29),

9. 8101625 - Pyrimidinones as Casein Kinase II (CK2) modulators (2012-01-24),

10. 8012956 - Tropane compounds (2011-09-06),

11. 7915250 - Azetidines as MEK inhibitors for the treatment of proliferative diseases (2011-03-29),

12. 7872014 - Anaplastic lymphoma kinase modulators and methods of use (2011-01-18),

13. 7846959 - Raf modulators and methods of use (2010-12-07),

14. 7803839 - Azetidines as MEK inhibitors for the treatment of proliferative diseases (2010-09-28),

15. 7704995 - Protein kinase modulators and methods of use (2010-04-27),

Title: The Innovative Contributions of Abigail R. Kennedy

Introduction

Abigail R. Kennedy is a prominent inventor based in Oakland, CA, known for her significant contributions to the field of pharmaceuticals. With a total of 16 patents to her name, she has made remarkable strides in developing compounds that target critical pathways in the treatment of proliferative diseases, including cancer.

Latest Patents

Among her latest patents, Kennedy has developed MEK inhibitors and methods of their use. These compounds, which include pharmaceutically acceptable salts and solvates, are designed to treat proliferative diseases such as cancer. Additionally, she has disclosed pharmaceutical compositions containing these compounds, along with methods for their application in cancer treatment. Another notable patent involves solid dosage formulations of substituted quinazoline receptor-type kinase modulators. This invention provides compounds that modulate receptor kinase activity, particularly ephrin and EGFR, and offers methods for treating diseases characterized by abnormal cell proliferation, apoptosis, cell migration, and angiogenesis associated with tumor growth.

Career Highlights

Throughout her career, Abigail R. Kennedy has worked with notable companies such as Exelixis, Inc. and Symphony Evolution, Inc. Her work has significantly impacted the pharmaceutical industry, particularly in the development of targeted therapies for cancer treatment.

Collaborations

Kennedy has collaborated with esteemed colleagues, including Csaba J. Peto and Kenneth D. Rice, further enhancing her contributions to the field.

Conclusion

Abigail R. Kennedy's innovative work in developing MEK inhibitors and receptor-type kinase modulators showcases her dedication to advancing cancer treatment. Her numerous patents reflect her commitment to improving therapeutic options for patients facing proliferative diseases.

Profile summary based on public USPTO records.